Tresiba lowers risk of hypos in type II diabetes
Tresiba significantly reduced the rate of severe hypoglycaemia by 80% and nocturnal symptomatic hypoglycaemia by 37%.
Read Moreby Anna Smith | Sep 20, 2019 | News | 0
Tresiba significantly reduced the rate of severe hypoglycaemia by 80% and nocturnal symptomatic hypoglycaemia by 37%.
Read Moreby Selina McKee | Oct 27, 2016 | News | 0
Novo Nordisk’s long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes.
Read Moreby Selina McKee | Aug 9, 2016 | News | 0
Treatment cost regulators for the NHS in Scotland have approved routine funding for six medicines, offering patients new treatment options for blood cancer, skin cancer, high cholesterol, diabetes, psoriatic arthritis, and infections in people with cystic fibrosis.
Read Moreby Selina McKee | Jun 16, 2016 | News | 0
Novo Nordisk has showcased new data from two Phase IIIb trials showing that diabetes patients treated with Tresiba experienced significantly lower rates of several types of hypoglycaemia than those using Sanofi’s Lantus.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
